Holen Sie sich die Stockscreener-App
4.25
0.00%
0.00
Schlusskurs vom Vortag:
$4.25
Offen:
$4.24
24-Stunden-Volumen:
323.49K
Relative Volume:
0.19
Marktkapitalisierung:
$449.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.88M
KGV:
-3.8206
EPS:
-1.1124
Netto-Cashflow:
$-42.79M
1W Leistung:
-6.39%
1M Leistung:
-13.97%
6M Leistung:
-40.73%
1J Leistung:
+172.44%
1-Tages-Spanne:
$4.14
$4.28
1-Wochen-Bereich:
$4.13
$4.58
52-Wochen-Spanne:
$1.44
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs PSNYW, GOODO, SHMD, CHAD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
4.29 | 773.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.35 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.33 | 220.96M | 52.15M | -21.46M | 0 | -0.4675 |
CHAD
Direxion Daily CSI 300 China A
|
7.8954 | 197.39M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
46.62 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
| 2026-01-23 | Fortgesetzt | Leerink Partners | Outperform |
| 2025-12-22 | Eingeleitet | Jefferies | Buy |
| 2025-11-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn
Relmada Therapeutics Inc. (RLMD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Relmada Therapeutics Inc. (RLMD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Relmada Therapeutics (RLMD) Slips 0.87% as Shares Defend Support at $4.32Put Call Ratio - dars.gov.et
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Relmada (RLMD) Chart: Moves 0.54% Down to $4.61 in the Latest Session; Levels: Price Remains Between $4.38 Support and $4.84 Resistance on the DayIchimoku Entry - siam.in
Relmada (RLMD) Results Breakdown: The Bottom-Line Figure Beats Its Comparison on the Day; Share Response: Shares Move Lower 0.22% in the Latest ReadingCost Structure Review - vinanet.vn
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay - Investing.com
Relmada Therapeutics (RLMD) Slides 7.6% to $4.57, Pressuring Key Support LevelMAMA Signal - vinanet.vn
Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Q2 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8%Time to Sell? - MarketBeat
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics Q2 Earnings Call Highlights - MarketBeat
Form 8K Relmada Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Relmada Therapeutics (RLMD) Boosts Cash Reserves Ahead of Key IN - GuruFocus
Earnings call transcript: Relmada posts Q2 2026 EPS beat as shares slip - Investing.com Canada
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings - TradingKey
Relmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingView
Relmada Highlights Q2 Results and NDV-01 Pipeline Progress - TipRanks
Relmada Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relmada Reports Q2 Loss As Cash Balance Reaches $217.7 Million - Quiver Quantitative
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock Titan
RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingView
RLMD: Advanced clinical pipeline and robust cash position support operations through 2029 - TradingView
RLMD: Higher net loss driven by R&D ramp-up, but cash position supports key clinical milestones ahead - TradingView
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - moomoo.com
RLMD Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Relmada Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth - Moomoo
597,409 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Stempoint Capital LP - MarketBeat
BlackRock (NYSE: BLK) discloses 7.0% beneficial stake in Relmada Therapeutics (RLMD) - Stock Titan
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - Investing News Network
Relmada Therapeutics (RLMD) Names Bipin Dalmia as Chief Business Officer Amid Strategic Growth Focus - GuruFocus
Relmada Therapeutics, Inc. Announces Appointment of Bipin Dalmia as Chief Business Officer - marketscreener.com
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relmada Therapeutics Inc-Aktie (RLMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):